efalizumab + ranibizumab

This is a combination of two monoclonal antibody drugs: - **Efalizumab** is a humanized monoclonal antibody that targets CD11a (the alpha subunit of LFA-1), inhibiting T-cell activation and migration. It was primarily developed for the treatment of moderate to severe plaque psoriasis but has been withdrawn from the market due to safety concerns (notably progressive multifocal leukoencephalopathy). - **Ranibizumab** is a recombinant humanized monoclonal antibody fragment that binds vascular endothelial growth factor A (VEGF-A), inhibiting angiogenesis and vascular permeability in the eye. It is used for ocular conditions involving abnormal blood vessel growth such as neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema (DME), macular edema following retinal vein occlusion (RVO), diabetic retinopathy, and myopic choroidal neovascularization[1][2][3][4][5]. No clinical or regulatory evidence supports the use or development of this specific combination as a single product.

Brand names

RaptivaLucentisByoovizCimerliRanivisioRimmyrahSusvimoXimluci

Other names

efalizumab and ranibizumab combination therapy